Insider Selling: BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) COO Sells 1,543 Shares of Stock

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) COO Xiaobin Wu sold 1,543 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $265.52, for a total transaction of $409,697.36. Following the transaction, the chief operating officer now directly owns 630 shares of the company's stock, valued at $167,277.60. This represents a 71.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Xiaobin Wu also recently made the following trade(s):

• On Tuesday, June 17th, Xiaobin Wu sold 630 shares of BeOne Medicines stock. The stock was sold at an average price of $250.87, for a total transaction of $158,048.10.
• On Friday, June 6th, Xiaobin Wu sold 1,934 shares of BeOne Medicines stock. The stock was sold at an average price of $253.15, for a total transaction of $489,592.10.
• On Tuesday, April 1st, Xiaobin Wu sold 51,921 shares of BeOne Medicines stock. The stock was sold at an average price of $281.40, for a total transaction of $14,610,569.40.

BeOne Medicines Stock Down 2.3%

Shares of NASDAQ ONC traded down $5.70 during trading hours on Friday, hitting $247.08. The company had a trading volume of 230,772 shares, compared to its average volume of 298,435. The stock has a market capitalization of $27.07 billion, a PE ratio of -66.42 and a beta of 0.30. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.96 and a quick ratio of 1.71. BeOne Medicines Ltd. - Sponsored ADR has a 1-year low of $141.31 and a 1-year high of $287.88. The firm's 50 day moving average price is $245.59.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $1.93. BeOne Medicines had a negative return on equity of 7.55% and a negative net margin of 9.40%. The business had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.12 billion. On average, sell-side analysts predict that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current year.

Analysts Set New Price Targets

ONC has been the subject of several research reports. Bank of America raised shares of BeOne Medicines from a "neutral" rating to a "buy" rating and raised their price target for the stock from $207.00 to $320.00 in a research note on Monday, March 3rd. Macquarie increased their price objective on BeOne Medicines from $259.00 to $313.00 and gave the company an "outperform" rating in a report on Friday, February 28th. JPMorgan Chase & Co. increased their price objective on BeOne Medicines from $311.00 to $317.00 and gave the company an "overweight" rating in a report on Monday, April 21st. Sanford C. Bernstein set a $259.00 price objective on BeOne Medicines in a report on Thursday, March 13th. Finally, TD Securities reissued a "buy" rating and issued a $334.00 price objective on shares of BeOne Medicines in a report on Thursday, April 24th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $319.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.